Phosphoproteins in extracellular vesicles as candidate markers for breast cancer

I‐Hsuan Chen(Purdue University West Lafayette), Liang Xue(Purdue University West Lafayette), Chuan‐Chih Hsu(Purdue University West Lafayette), Sebastian Juan Paez(Purdue University West Lafayette), Pan Li(Purdue University West Lafayette), Hillary Andaluz(Purdue University West Lafayette), Michael K. Wendt(Purdue University West Lafayette), Anton Iliuk(Tymora Analytical Operations (United States)), Jian‐Kang Zhu(Chinese Academy of Sciences), W. Andy Tao(Purdue University West Lafayette)
Proceedings of the National Academy of Sciences
March 7, 2017
Cited by 493Open Access
Full Text

Abstract

The state of protein phosphorylation can be a key determinant of cellular physiology such as early-stage cancer, but the development of phosphoproteins in biofluids for disease diagnosis remains elusive. Here we demonstrate a strategy to isolate and identify phosphoproteins in extracellular vesicles (EVs) from human plasma as potential markers to differentiate disease from healthy states. We identified close to 10,000 unique phosphopeptides in EVs isolated from small volumes of plasma samples. Using label-free quantitative phosphoproteomics, we identified 144 phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer compared with healthy controls. Several biomarkers were validated in individual patients using paralleled reaction monitoring for targeted quantitation. This study demonstrates that the development of phosphoproteins in plasma EV as disease biomarkers is highly feasible and may transform cancer screening and monitoring.


Related Papers

No related papers found

Powered by citation graph analysis